GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Inc (ROCO:6892) » Definitions » Beneish M-Score

Taiwan Bio Therapeutics (ROCO:6892) Beneish M-Score : 0.00 (As of Apr. 08, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Taiwan Bio Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 6 years, the highest Beneish M-Score of Taiwan Bio Therapeutics was -1.12. The lowest was -1.12. And the median was -1.12.


Taiwan Bio Therapeutics Beneish M-Score Historical Data

The historical data trend for Taiwan Bio Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics Beneish M-Score Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial - - - -1.12 -

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - -1.12 -1.84 -0.96 -

Competitive Comparison of Taiwan Bio Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Taiwan Bio Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiwan Bio Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Taiwan Bio Therapeutics's Beneish M-Score falls into.


;
;

Taiwan Bio Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Taiwan Bio Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3434+0.528 * 1.6745+0.404 * 0.8709+0.892 * 1.2296+0.115 * 0.7542
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.087+4.679 * -0.06753-0.327 * 0.744
=-1.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was NT$39.9 Mil.
Revenue was NT$105.1 Mil.
Gross Profit was NT$56.1 Mil.
Total Current Assets was NT$786.2 Mil.
Total Assets was NT$1,472.0 Mil.
Property, Plant and Equipment(Net PPE) was NT$552.4 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$99.2 Mil.
Selling, General, & Admin. Expense(SGA) was NT$61.9 Mil.
Total Current Liabilities was NT$77.4 Mil.
Long-Term Debt & Capital Lease Obligation was NT$285.5 Mil.
Net Income was NT$-351.8 Mil.
Gross Profit was NT$0.0 Mil.
Cash Flow from Operations was NT$-252.4 Mil.
Total Receivables was NT$24.1 Mil.
Revenue was NT$85.5 Mil.
Gross Profit was NT$76.4 Mil.
Total Current Assets was NT$333.2 Mil.
Total Assets was NT$941.8 Mil.
Property, Plant and Equipment(Net PPE) was NT$510.6 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$66.2 Mil.
Selling, General, & Admin. Expense(SGA) was NT$46.3 Mil.
Total Current Liabilities was NT$61.6 Mil.
Long-Term Debt & Capital Lease Obligation was NT$250.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(39.868 / 105.094) / (24.135 / 85.47)
=0.379356 / 0.28238
=1.3434

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(76.359 / 85.47) / (56.07 / 105.094)
=0.893401 / 0.533522
=1.6745

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (786.223 + 552.423) / 1471.971) / (1 - (333.179 + 510.642) / 941.761)
=0.090576 / 0.103997
=0.8709

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=105.094 / 85.47
=1.2296

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(66.234 / (66.234 + 510.642)) / (99.197 / (99.197 + 552.423))
=0.114815 / 0.152231
=0.7542

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(61.895 / 105.094) / (46.308 / 85.47)
=0.588949 / 0.541804
=1.087

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((285.532 + 77.418) / 1471.971) / ((250.513 + 61.617) / 941.761)
=0.246574 / 0.331432
=0.744

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-351.802 - 0 - -252.4) / 1471.971
=-0.06753

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Taiwan Bio Therapeutics has a M-score of -1.93 suggests that the company is unlikely to be a manipulator.


Taiwan Bio Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiwan Bio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.

Taiwan Bio Therapeutics Headlines

No Headlines